[
    "**A. Preparation of hydrogel precursor solutions**",
    "1.",
    "Allow PEG-4MAL macromer, adhesive ligand \\(RGD) and crosslinker \\(GPQ-W) to reach room temperature.\r\n  ",
    "2.",
    "Based on the desired number of hydrogels and final PEG-4MAL macromer concentration, weight out the amount of PEG-4MAL macromer and peptides needed, considering that solutions will be prepared at 2.5X and 5X final density, respectively, as the components will be mixed at the final volume fractions listed in Table 1.\r\n  ",
    "The RGD final density is 2.0 mM, and the GPQ-W final density corresponds to 1:1 maleimide/cysteine ratio after accounting for maleimide groups reacted with the adhesive peptide.",
    "Note: Consider the purity of the peptides and maleimide substitution efficiency when calculating the mass of peptides.",
    "3. Dissolve the peptide solutions, in separate microcentrifuge tubes, using 20.0 mM HEPES \\(in DPBS, pH 7.4) and adjust the pH of each solution to 7.4.\r\n  ",
    "4.",
    "Filter each peptide solution by transferring all solutions to a separate Costar Spin-X centrifuge tube and centrifuge at 9,000 RCF for 1 min.\r\n  5.",
    "Dissolve the PEG-4MAL macromer in a separate microcentrifuge tube using filtered 20.0 mM HEPES \\(in DPBS, pH 7.4).\r\n  ",
    "6.",
    "Mix PEG-4MAL macromer and RGD solutions at a 2:1 PEG-4MAL/RGD volume ratio to generate functionalized PEG-4MAL \\(PEG-4MAL-RGD) precursor solution, and incubate for at least 15 min at 37OC.\r\n  ",
    "**B. Preparation of human tissue suspension**",
    "_B.1 Preparation of intestinal spheroid suspension_",
    "1.",
    "Human iPSCs or human ESCs are cultured and differentiated into intestinal tissue as previously described<sup>9,10</sup>.",
    "Harvest the floating spheroids present in the cultures on day 4 and day 5 of mid/hindgut induction by vigorously pipetting with large orifice pipette tips, and transfer to a microcentrifuge tube.\r\n  ",
    "2.",
    "Resuspend at 5X final density \\(final density: 20-30 spheroids/hydrogel) in intestine growth medium<sup>11</sup> and keep on ice.\r\n  ",
    "Intestine growth medium: Advanced DMEM-F12 medium supplemented with L-glutamine \\(2 mM final concentration), 15 mM HEPES, B27 supplement \\(1X final dilution = 2 mL per 50 mL of medium), penicillin-streptomycin \\(final concentration 100 U/mL penicillin, and 100 \u00b5g/mL streptomycin), and growth factors \\(100 ng/mL Noggin, 100 ng/mL EGF, and 500 ng/mL R-spondin1).",
    "_B.2 Preparation of human intestinal organoid suspension_",
    "1.",
    "Human iPSCs or human ESCs are cultured and differentiated into HIOs as previously described<sup>9,10</sup>.",
    "Mechanically dislodge HIOs from MatrigelTM by vigorously pipetting with large orifice pipette tips to free the organoids from the MatrigelTM.\r\n  ",
    "2.",
    "Transfer HIOs to a microcentrifuge tube, resuspend at 5X final density \\(final density: 2-4 HIOs/hydrogel) in intestine growth medium<sup>11</sup> \\(see above for composition), and keep on ice.\r\n  ",
    "**C. Synthetic hydrogel casting**",
    "1.",
    "Mix intestinal spheroids or HIOs suspension with the PEG-4MAL-RGD precursor solution at a 3:1 PEG-4MAL-RGD/cell suspension using large orifice pipette tips, and keep on ice.\r\n  ",
    "2.",
    "Add crosslinker solution \\(20% of the final hydrogel volume, as shown in Table 1) to the bottom \\(centered) of each well of a 24-well plate.\r\n  ",
    "Note: Follow the next steps in the shortest time possible to avoid crosslinker evaporation.",
    "3.",
    "Pipette the PEG-4MAL-RGD + cell suspension \\(prepared above; 80% of the final hydrogel volume, as shown in Table 1) into crosslinker solution in each well using large orifice pipette tips.\r\n  ",
    "Note: It is critical to do sufficient mixing to obtain a homogenous solution.",
    "Change to a fresh pipette tip after casting a hydrogel.",
    "4. Allow hydrogel formation by incubating the plate at 37OC for up to 20 min.\r\n  5.",
    "Overlay the hydrogels with 500 \u00b5L of intestine growth medium \\(see above for composition).\r\n  ",
    "6.",
    "Replace medium every 4 d, or when the phenol red in the medium turns yellow.\r\n  ",
    "**D. Organoid passaging**",
    "Passaging HIOs cultured in PEG-4MAL hydrogels is performed similarly to tissue embedded in MatrigelTM, as previously described<sup>10</sup>.",
    "Briefly:",
    "1.",
    "Mechanically dislodge organoids from the PEG-4MAL hydrogel by vigorously pipetting with large orifice pipette tips to free the organoids from the hydrogel.\r\n  ",
    "2. Pool all the PEG-4MAL + organoids + medium from each well into a sterile Petri dish containing 10 mL of warm DMEM-F12.",
    "By using a sterile tungsten needle or sterile fine forceps, dislodge any large pieces of hydrogel that are still adherent to the organoids.\r\n  ",
    "3.",
    "Under a stereomicroscope, manually cut the organoids into halves using a sterile scalpel.\r\n  ",
    "4.",
    "Transfer organoid halves to a microcentrifuge tube, resuspend at 5X final density \\(final density: 2-4 HIOs/hydrogel) in intestine growth medium \\(see above for composition), and keep on ice.\r\n  ",
    "5. Repeat \u201cSynthetic hydrogel casting\u201d steps to form fresh HIO-containing hydrogels.\r\n  ",
    "6.",
    "Cut organoid halves will grow and expand.",
    "Repeat HIO passaging every 7-10 d as necessary.",
    "We have repeat this expansion for up to 21 d.\r\n  ",
    "**E. Organoid encapsulation and injection into colonic mucosal wound bed**",
    "Colonic mucosal wounds \\(~1 mm2) can be generated using a high-resolution colonoscopy system \\(Fig.",
    "1), as previously described<sup>12</sup>.",
    "The next day:",
    "1.",
    "Human iPSC- or human ESC-derived HIOs that are generated within PEG-4MAL hydrogels \\(as described above) or MatrigelTM \\(as previously described<sup>9,10</sup>) are mechanically dislodged from the matrix by vigorously pipetting with large orifice pipette tips to free the organoids.\r\n  ",
    "2.",
    "Transfer HIOs to a microcentrifuge tube, resuspend at 5X final density \\(final density: 2-4 HIOs/hydrogel) in foregut growth medium \\(see above for composition), and keep on ice. \r\n  ",
    "3. Prepare hydrogel precursor solutions as described in Section A.\r\n  4.",
    "Load 10 \u00b5L of crosslinker in a custom-made device comprising a 10 cm piece of intramedic polyethylene tube \\(OD: 1.09mm) with a 27G neddle \\(OD: 0.41 mm) in each extreme.",
    "To construct this, the metalic needle will be removed from the hub and the blunt end of the needle will be carefully attached to one end of the tubing, leaving the needle bevel exposed.",
    "Another complete neddle will be connected to the tube through the needle bevel \\(Fig.",
    "1). \r\n  ",
    "5.",
    "Mix HIO suspension with the PEG-4MAL-RGD precursor solution at a 3:1 PEG-4MAL-RGD/HIO suspension using large orifice pipette tips, and keep on ice.\r\n  ",
    "6. Load the PEG-4MAL-RGD precursor + HIO mixture solution \\(prepared above) in a 1 mL TB syringe.",
    "40 \u00b5L of this solution will be used per injection. \r\n  ",
    "7. Connect the custom-made device containing the crossliker to the TB syringe with the PEG-4MAL-RGD + HIO suspension.",
    "Insert the nedle bevel through the colonoscope forceps auxiliary pocket \\(Fig.",
    "1).\r\n  ",
    "8.",
    "Using a plastic gavage neddle, lubricate the mouse anus with a drop of PBS.",
    "Insert the colonoscope probe and identify the wounds generated the day before through the high-resolution colonoscopy camera.\r\n  ",
    "A detailed protocol of murine endoscopy for in vivo imaging and assessment of intestinal wound healing and inflammation, including injury and wound bed injection procedures, is avilable online<sup>13</sup>. ",
    "9.",
    "Once a wound has been found, position the colonoscope probe close to the distal end of the wound.",
    "Push the tubing through the auxiliary pocket until the needle bevel is observed throught the camera and proceed to carefully penetrate the mucosa and locate the needle bevel right at the wound bed \\(submucosa; Fig. 1a,b).\r\n  ",
    "10.",
    "Inject 40 \u00b5L of the functionalized PEG-4MAL-RGD + HIO suspension.",
    "The functionalized PEG-4MAL-RGD + HIO suspension will meet the crosslinker in the tubing and the hydrogel will be formed in situ at the injection site.",
    "A successful procedure will be visualized by the formation of a small protrusion at the injection site. \r\n  ",
    "11.",
    "Pull the needle out and repeat at a different wound site \\(only one injection per wound is recommended).",
    "A new custom-made device containing the crossliker will be needed for each injection made \\(repeat step E.4 for each injection)."
]